Jelkmann W, Fandrey J, Wiedemann G
Institut für Physiologie, Medizinische Universität zu Lübeck, FRG.
Biomed Biochim Acta. 1990;49(2-3):S265-70.
Knowledge of the endogenous blood level of erythropoietin (Epo) has gained recent interest in view of the advances in Epo replacement therapy in anemic patients. By radioimmunoassay, we have carried out comparative measurements of the serum Epo level in patients suffering from chronic enterocolitis or leukemia. In chronic enterocolitis, the Epo level showed an exponential increase with the degree of anemia (up to 250 U Epo/1 serum at 70 g hemoglobin/1 blood). Similarly anemic patients with leukemia and severe bone marrow insufficiency of erythropoiesis had much higher Epo levels (usually above 500 U/1). Our findings indicate that the level of Epo is not only dependent on the blood hemoglobin concentration but also on the type of anemia. In fact, additional in vitro studies showed that immunomodulatory peptides can significantly influence the production of Epo in the hepatoma cell culture HepG2.
鉴于促红细胞生成素（Epo）替代疗法在贫血患者中的进展，对Epo内源性血液水平的了解近来受到关注。通过放射免疫测定法，我们对患有慢性小肠结肠炎或白血病的患者的血清Epo水平进行了比较测量。在慢性小肠结肠炎中，Epo水平随贫血程度呈指数增加（血红蛋白水平为70 g/1血液时，血清Epo水平高达250 U/1）。同样，患有白血病且严重骨髓红细胞生成不足的贫血患者的Epo水平要高得多（通常高于500 U/1）。我们的研究结果表明，Epo水平不仅取决于血液血红蛋白浓度，还取决于贫血类型。事实上，额外的体外研究表明，免疫调节肽可显著影响肝癌细胞系HepG2中Epo的产生。
